​

Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

STOK Stock Forecast

Stoke Therapeutics (STOK) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $42.75, with a high of $60.00 and a low of $35.00. This represents a 17.19% increase from the last price of $36.48.

$5 $16 $27 $38 $49 $60 High: $60 Avg: $42.75 Low: $35 Last Closed Price: $36.48

STOK Stock Rating

Stoke Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (80.00%), 3 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 3 12 Strong Sell Sell Hold Buy Strong Buy

STOK Price Target Upside V Benchmarks

TypeNameUpside
StockStoke Therapeutics17.19%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1710
Avg Price Target$40.00$43.86$39.80
Last Closing Price$36.48$36.48$36.48
Upside/Downside9.65%20.23%9.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26111---12
Feb, 2619---10
Jan, 2619---10
Dec, 2519---10
Nov, 25281--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 23, 2026Wolfe Research$40.00$36.2310.41%9.65%
Feb 05, 2026Yatin SunejaGuggenheim$60.00$32.0087.50%64.47%
Jan 12, 2026Wedbush$36.00$28.1427.93%-1.32%
Jan 05, 2026Canaccord Genuity$36.00$30.9016.50%-1.32%
Jan 05, 2026Keay NakaeLoop Capital Markets$35.00$30.9013.27%-4.06%
Dec 16, 2025Andrew FeinH.C. Wainwright$50.00$32.9051.98%37.06%
Dec 15, 2025UBS$50.00$32.8252.35%37.06%
Nov 05, 2025Canaccord Genuity$28.00$21.4230.72%-23.25%
Oct 10, 2025Needham$35.00$29.9017.06%-4.06%
Aug 18, 2025Thomas ShraderBTIG$28.00$18.1054.70%-23.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 05, 2026GuggenheimBuyinitialise
Jan 12, 2026WedbushOutperformOutperformhold
Dec 15, 2025H.C. WainwrightBuyBuyhold
Oct 10, 2025NeedhamBuyBuyhold
Aug 18, 2025BTIGBuyBuyhold
Sep 11, 2024Cowen & Co.BuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold
Jun 28, 2024NeedhamBuyBuyhold
May 07, 2024Canaccord GenuityBuyBuyhold

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.39$-2.38$-1.65----
Avg Forecast$-2.66$-2.38$-2.03$-2.37$-2.55$-2.07$-1.66
High Forecast$-1.74$-2.26$-2.00$-2.04$-2.06$-0.17$-0.64
Low Forecast$-3.15$-2.48$-2.11$-2.77$-3.20$-3.40$-2.52
Surprise %-10.15%--18.72%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.40M$8.78M$36.55M----
Avg Forecast$11.70M$9.53M$17.42M$20.36M$23.29M$69.31M$108.62M
High Forecast$13.36M$10.87M$18.30M$28.57M$32.69M$97.28M$152.44M
Low Forecast$8.59M$7.83M$15.30M$10.71M$12.26M$36.48M$57.17M
Surprise %6.05%-7.82%109.87%----

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-93.11M$-104.70M$-88.98M----
Avg Forecast$-117.09M$-104.70M$-90.36M$-105.69M$-115.76M$-78.53M$-72.81M
High Forecast$-76.69M$-99.54M$-87.95M$-89.73M$-90.62M$-7.48M$-27.98M
Low Forecast$-138.67M$-109.24M$-92.78M$-121.66M$-140.91M$-149.58M$-111.01M
Surprise %-20.48%--1.53%----

STOK Forecast FAQ

Is Stoke Therapeutics stock a buy?

Stoke Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Stoke Therapeutics is a favorable investment for most analysts.

What is Stoke Therapeutics's price target?

Stoke Therapeutics's price target, set by 15 Wall Street analysts, averages $42.75 over the next 12 months. The price target range spans from $35 at the low end to $60 at the high end, suggesting a potential 17.19% change from the previous closing price of $36.48.

How does Stoke Therapeutics stock forecast compare to its benchmarks?

Stoke Therapeutics's stock forecast shows a 17.19% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Stoke Therapeutics over the past three months?

  • March 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Stoke Therapeutics’s EPS forecast?

Stoke Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.37, marking a 43.64% increase from the reported $-1.65 in 2024. Estimates for the following years are $-2.55 in 2026, $-2.07 in 2027, and $-1.66 in 2028.

What is Stoke Therapeutics’s revenue forecast?

Stoke Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $20.36M, reflecting a -44.31% decrease from the reported $36.56M in 2024. The forecast for 2026 is $23.29M, followed by $69.32M for 2027, and $108.62M for 2028.

What is Stoke Therapeutics’s net income forecast?

Stoke Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-106M, representing an 18.78% increase from the reported $-88.981M in 2024. Projections indicate $-116M in 2026, $-78.531M in 2027, and $-72.811M in 2028.